Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020

被引：7

作者：

Guzman-Holst, Adriana ^{[1
]}

de Barros, Eliana ^{[2
]}

Rubio, Pilar ^{[2
]}

DeAntonio, Rodrigo ^{[3
]}

Cintra, Otavio ^{[4
]}

Abreu, Ariane ^{[5
]}

机构：

[1] GSK, Panama City, Panama

[2] GSK, Rio De Janeiro, Brazil

[3] Ctr Vacunac Int SA CEVAXIN, Panama City, Panama

[4] GSK, Wavre, Belgium

[5] Inst Nacl Cardiol, Rio De Janeiro, Brazil

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 01期

关键词：

Streptococcus pneumoniae; vaccination; PCV; Brazil; invasive pneumococcal disease; Pneumonia; acute otitis media; nasopharyngeal carriage; impact;

D O I：

10.1080/21645515.2021.1879578

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In 2010, a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) was introduced in the Brazilian national immunization program; the 3 + 1 dose schedule was replaced by a 2 + 1 dose schedule in 2016. This systematic review presents the latest published evidence (2015-2020) on the impact after 10-year use of PHiD-CV in Brazil from a total of 29 publications. Overall, the PHiD-CV program had a positive impact on the morbidity and mortality associated with invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) in children <5 years-old. A reduction in the vaccine-type invasive disease was observed in all-ages; suggesting indirect protection unvaccinated older children and adults. The occurrence of non-vaccine type disease was evidenced in some studies. Higher vaccination coverage is required at national and state level for sustained population impact. Given the change in the vaccination schedule and the dynamics of pneumococcal disease epidemiology, continuous surveillance is warranted. GSK Study identifier: HO-18-19438

引用

页数：17

共 61 条

[1]

Almeida SD, 2017, IDWEEK

[2] Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis [J].